New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
09:03 EDTGALEGalena SEC investigation should not affect value of assets, says Maxim
Maxim sees the worst case scenario from the SEC's investigation into Galena's stock promotion practices as the agency finding some liability with management. The firm says such an outcome should not materially affect the value of the company's underlying assets and it keeps a Buy rating on the stock with an $11 price target.
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 16, 2015
09:04 EDTGALEGalena data encouraging, says Roth Capital
After Galena announced data from a Phase II study of its GALE-401 drug, Roth Capital says the data is encouraging and reduces the drug's clinical risk. The firm calls the drug promising and keeps an $8 price target and Buy rating on the shares.
June 15, 2015
07:19 EDTGALEGalena presents GALE-401 Phase 2 data at EHA
Galena Biopharma announced that data from the company's Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association, or EHA, 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia, or ET, and other myeloproliferative neoplasms, or MPNs. The poster presentation, entitled, "Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide, or GALE-401, in Subjects with Myeloproliferative Neoplasm, or MPN,-Related Thrombocytosis," was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release, or IR, response rates with the following platelet response: overall response rate, or ORR, of 78%; complete response, or CR, of 39%; partial response of 39%. The median time to response was 5 weeks, and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 versus anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is expected to be presented at the American Society of Hematology conference in December.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use